A single injection could provide months-long protection
In the long struggle against one of humanity's oldest and most relentless diseases, researchers at the University of Maryland have offered a new kind of answer — not a plea to the immune system, but a direct intervention. A laboratory-engineered antibody called MAM01 provided complete protection against malaria in early human trials, raising the possibility of a single injection standing between a child and infection for months at a time. With over 600,000 lives lost to malaria each year, most of them young children in sub-Saharan Africa, the stakes of this early promise are as large as the disease itself.
- Malaria continues to kill more than 600,000 people annually, with children under five in sub-Saharan Africa bearing the heaviest burden despite decades of imperfect vaccines and treatments.
- MAM01 achieved 100% protection in the highest-dose group of a Phase 1 trial, while every placebo recipient became infected — a stark and unambiguous contrast.
- Unlike traditional vaccines that depend on the immune system building its own defenses over time, MAM01 acts immediately by blocking the parasite's entry into cells with a lab-engineered protein.
- A single injection could offer months of protection, a logistical advantage that could prove transformative in resource-limited settings where multi-dose regimens are difficult to sustain.
- The trial's 38 participants were healthy adults with no prior malaria exposure — the real test now lies in larger Phase 2 and 3 trials among pregnant women, infants, and endemic populations.
Researchers at the University of Maryland have developed a monoclonal antibody, MAM01, that delivered complete protection against malaria in a small but carefully controlled human trial — a result that could fundamentally change how the world approaches prevention of one of its most persistent killers.
Malaria still claims more than 600,000 lives each year, the vast majority of them children under five in sub-Saharan Africa. Existing vaccines and treatments remain imperfect, leaving the most vulnerable chronically exposed. MAM01 takes a different path entirely: rather than training the immune system, it deploys a laboratory-made protein that directly blocks the parasite from entering the body's cells.
The Phase 1 trial enrolled 38 healthy adults who had never been exposed to malaria. Half received MAM01 at varying doses; the rest received a placebo. All were later exposed to malaria-carrying mosquitoes under controlled conditions. The outcome was clear — participants in the highest-dose group developed no infections, while every placebo recipient became infected. No serious side effects were observed.
Lead researcher Kirsten E. Lyke highlighted the practical power of a single injection offering months of protection — no boosters, no waiting for immunity to build. Co-author Matthew B. Laurens called the findings a meaningful step toward health equity, given how disproportionately malaria burdens children in low-resource settings.
Published in The Lancet Infectious Diseases, the study is an early but significant signal. Larger Phase 2 and 3 trials will determine whether MAM01's laboratory success holds in malaria-endemic regions and among the populations — pregnant women, infants, young children — where the disease exacts its greatest toll.
Researchers at the University of Maryland have developed a monoclonal antibody that stopped malaria cold in its tracks during early human testing. The compound, called MAM01, delivered complete protection against the parasite in a small but carefully controlled trial—a result that could reshape how the world prevents one of its most persistent killers.
Malaria still claims more than 600,000 lives each year, the vast majority of them children under five in sub-Saharan Africa. Despite decades of effort, existing vaccines and treatments remain imperfect, leaving vulnerable populations—especially young children and pregnant women—exposed to a disease that remains one of the leading causes of childhood death in low and middle-income countries. The new antibody represents a fundamentally different approach: instead of training the immune system to recognize the parasite, researchers engineered a laboratory-made protein that does the job directly.
The Phase 1 trial enrolled 38 healthy adults aged 18 to 50 who had never been exposed to malaria. Half received a single injection of MAM01 at varying doses; the other half received a placebo. Months later, all participants were exposed to malaria-carrying mosquitoes under controlled laboratory conditions—a deliberate challenge designed to test whether the antibody could prevent infection before the parasite reached the bloodstream. The results were unambiguous: participants who received the highest dose of MAM01 developed no infections whatsoever, while all placebo recipients became infected. The antibody worked by targeting a specific protein on the parasite's surface, essentially blocking its entry into the body's cells. No serious side effects were observed.
Kirsten E. Lyke, the lead researcher and a professor of medicine at the university's School of Medicine, emphasized the practical advantage of this approach. A single injection could provide protection for months—far simpler than vaccines requiring multiple doses or boosters, and immediate rather than requiring time for the immune system to mount a response. "It's a fundamentally different way to stop infection before it starts," she said. Matthew B. Laurens, a pediatrics professor and co-author, called the results an important proof-of-concept and a step forward for health equity, given malaria's outsized burden on children in resource-limited settings.
The work, published in The Lancet Infectious Diseases, represents an early but promising signal. The next phase will test whether MAM01 works as well in actual malaria-endemic regions and in the populations most at risk—pregnant women, infants, and young children—where the real weight of the disease falls. That larger trial will determine whether this laboratory success translates into a tool that can actually save lives at scale.
Citações Notáveis
A single injection of a long-acting antibody could provide immediate, months-long protection. It's a fundamentally different way to stop infection before it starts.— Kirsten E. Lyke, lead researcher, University of Maryland School of Medicine
This is an important proof-of-concept for the field and a step forward for health equity.— Matthew B. Laurens, co-author and Professor of Pediatrics
A Conversa do Hearth Outra perspectiva sobre a história
Why does a single injection matter so much more than a vaccine that requires boosters?
Because in places where malaria kills the most children, getting people back for follow-up doses is logistically brutal. A mother in a remote village might get her child vaccinated once, but returning months later for a booster? That's often impossible. One shot, months of protection—that's a completely different calculus.
So this antibody is doing the work the immune system would normally do?
Exactly. We're not teaching the body to fight malaria. We're giving it a pre-made fighter that's already trained. The antibody recognizes a specific protein on the parasite and blocks it before infection even starts.
Why test it on people who've never had malaria?
You need a clean baseline. If you test on people who've been exposed before, their immune systems are already primed, and you can't isolate what the antibody itself is doing. These 38 adults gave researchers a pure read on the drug's effect.
The placebo group all got infected. Isn't that ethically troubling?
It sounds worse than it is. They were infected under controlled conditions in a hospital setting, not in the field. Malaria is treatable when caught early and managed properly. The researchers could monitor them closely and treat them immediately. It's how you prove something works.
What happens next?
Larger trials in actual malaria zones, with the people who need it most—pregnant women, infants, young children. That's where you find out if this laboratory success becomes a public health tool.